Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NTRBW) delivers innovative transdermal solutions addressing critical pharmaceutical safety challenges through its proprietary AVERSA® technology. This dedicated news hub provides investors and industry stakeholders with essential updates about regulatory progress, product development milestones, and strategic partnerships.
Access real-time announcements covering clinical trial developments, intellectual property expansions, manufacturing agreements, and consumer product launches. Our curated feed includes earnings reports, FDA submission updates, and analysis of technologies combating opioid misuse through abuse-deterrent systems.
Key focus areas include advancements in transdermal drug delivery systems, international patent grants, and collaborations with industry leaders like Kindeva Drug Delivery. Stay informed about Nutriband's progress in integrating Bitrex®-based safety mechanisms across therapeutic applications while maintaining compliance with global regulatory standards.
Bookmark this page for verified updates about Nutriband's mission to enhance medication safety through cutting-edge transdermal innovations. Monitor critical developments in pharmaceutical abuse prevention and topical delivery systems from a single authoritative source.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported financial results for the fiscal year ending January 31, 2023, highlighting a record revenue of $2.1 million, up 46% from the previous year. Key achievements include a favorable court verdict recovering 15% of total outstanding shares and the announcement of a Seven-for-Six Forward stock split. The company received patent allowance for its AVERSA™ technology in North America and partnered with Kindeva Drug Delivery for enhanced abuse-deterrent characteristics. Despite a net loss of $4.48 million (or $0.53 per share), down from $6.37 million in FY 2022, the results reflect significant operational progress. Research expenses increased to $0.98 million from $0.4 million, while SG&A expenses decreased slightly to $3.9 million. The company aims for commercial growth in 2023 and anticipates AVERSA™ to achieve annual sales between $80 million and $200 million.
Nutriband (NASDAQ:NTRB, NTRBW), recognized for its innovative transdermal solutions, is set to present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 08:30 AM PST. CEO Gareth Sheridan will lead the presentation, followed by a Q&A session.
To join the live presentation, access the webcast here. For those interested in one-on-one investor meetings during the event in Las Vegas, registration is available here.
Nutriband is advancing its abuse deterrent fentanyl patch utilizing the patented AVERSA technology, aimed at mitigating drug misuse and exposure risks.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a partnership with Kindeva Drug Delivery to advance the AVERSA™ Fentanyl formulation into commercial manufacturing. The AVERSA™ Fentanyl product utilizes Nutriband's proprietary abuse-deterrent technology and is projected to achieve peak U.S. sales between $80M and $200M. This collaboration aims to develop the first abuse-deterrent fentanyl patch, enhancing safety and accessibility for patients. The technology is supported by a robust intellectual property portfolio, with patents granted in multiple countries.
FAQ
What is the current stock price of Nutriband (NTRBW)?
